Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Diacerein 1% ointment in generalized epidermolysis bullosa simplex (Phase 2/3, double-blind, vehicle-controlled, with open-label extension)
ChiCTR2600121412Phase 3Not yet recruiting
- Sponsor
- Southern Medical University Dermatology Hospital
- Start
- Mar 2026
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in epidermolysis bullosa simplex (EBS) comparing Diacerein 1% ointment with Vehicle ointment (control) (2 arms). Primary endpoint: Treatment success on IGA of treatment area at Week 8. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
diacerein
03
Conditions
epidermolysis bullosa simplex (EBS)
Beyond the preview
Go deeper on ChiCTR2600121412.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600121412.